10-K: Cue Biopharma Prioritizes Autoimmune Programs, Seeks Partnerships for Oncology Assets in 2024 10-K Filing

Sentiment:

Annual Results 31 March 2025 4:00 PM

Cue Biopharma shifts focus to autoimmune drug candidates while exploring strategic partnerships for its oncology programs, according to its 2024 annual report.

Capital raiseThe company will need to raise additional capital to fund its future operations and remain as a going concern.The company expects to finance its future cash needs through a combination of equity offerings, collaborations, and other strategic alliances.The company may seek to access the public or private capital markets whenever conditions are favorable, even if it does not have an immediate need for additional capital at that time.

Worse than expectedThe company's cash runway is expected to fund operations into the fourth quarter of 2025, which is less than 12 months from the date of issuance of the financial statements.The company has incurred recurring losses from operations and has never generated revenue or profit from product sales.The company will need to raise additional capital to fund its future operations and remain as a going concern.

Summary

Cue Biopharma is a clinical-stage biopharmaceutical company focusing on precision immunotherapies for cancer and autoimmune diseases.
The company's Immuno-STAT platform is designed to selectively modulate disease-relevant T cells.
Cue Biopharma is prioritizing its autoimmune programs, CUE-401 and CUE-501, while seeking partnerships for its oncology assets, CUE-101 and CUE-102.
CUE-401 is in IND-enabling studies, with an IND filing planned for the third quarter of 2026.
The company is seeking a third-party partnership to advance the preclinical CUE-501 program.
As of December 31, 2024, Cue Biopharma had $22.5 million in cash and cash equivalents, expected to fund operations into the fourth quarter of 2025.
The company anticipates incurring future losses and will need additional financing to support its operations.
Cue Biopharma is subject to various risks, including competition, regulatory hurdles, and the need for additional capital.
The company has a loan agreement with First Citizens Bank that requires it to meet certain operating covenants and place restrictions on its operating and financial flexibility.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is strategically focusing on promising areas like autoimmune diseases and seeking partnerships, the financial situation and dependence on future funding raise concerns.

Positives

The company is strategically prioritizing its autoimmune portfolio, which it believes represents near-term value creation opportunities.
CUE-401 has the potential to become a new standard of care in the treatment of autoimmune disease.
The CUE-500 series has therapeutic potential across multiple therapeutic areas.
The company has regained worldwide development and commercialization rights for CUE-401.
The company has demonstrated clinical evidence of targeted activation and expansion of T cells with the CUE-100 series.

Negatives

The company has incurred significant losses since its inception and has never generated revenue or profit from product sales.
The company's recurring losses from operations raise substantial doubt regarding its ability to continue as a going concern.
The company will need to raise additional capital to fund its future operations and remain as a going concern.
The company is substantially dependent on the success of its drug product candidates, only two of which are currently being tested in clinical trials.
The company has limited experience in conducting clinical trials and no history of commercializing biologic products.
The company faces significant competition from other biotechnology and pharmaceutical companies.
The company relies on third parties to conduct its clinical trials and manufacture its drug supplies.
The company has a loan agreement that requires it to meet certain operating covenants and place restrictions on its operating and financial flexibility.

Risks

The company's recurring losses from operations raise substantial doubt regarding its ability to continue as a going concern.
The company is substantially dependent on the success of its drug product candidates, only two of which are currently being tested in clinical trials.
The company faces significant competition from other biotechnology and pharmaceutical companies.
The company relies on third parties to conduct its clinical trials and manufacture its drug supplies.
The company will need substantial additional financing to support its growth and ongoing operations.
The company has a loan agreement that requires it to meet certain operating covenants and place restrictions on its operating and financial flexibility.
The company may not be successful in its efforts to identify additional drug product candidates.
The company may not be able to establish strategic alliances or collaborations.
The company may experience delays in clinical trials or regulatory approvals.
The company's drug product candidates may have adverse side effects.
The company may not be able to protect its intellectual property.
The company may be subject to product liability lawsuits.
The company may be affected by government regulations and healthcare reform.
The company may be subject to cybersecurity threats.
The company may be affected by war, terrorism, other acts of violence, or natural or manmade disasters.

Future Outlook

Cue Biopharma expects to finance its future cash needs through a combination of equity offerings, collaborations, and other strategic alliances. The company believes that its existing cash and cash equivalents will enable it to fund its operations into the fourth quarter of 2025.

Management Comments

The company aims to leverage its differentiated platform to establish new standards of care, forge strategic partnerships, and accelerate clinical development.
The company is seeking development and commercialization partners for its oncology assets, CUE-101 and CUE-102.
The company plans to file an IND for CUE-401 in the third quarter of 2026.
The company intends to establish a third-party partnership to advance the preclinical CUE-501 program.

Industry Context

The announcement reflects a growing trend in the biopharmaceutical industry towards prioritizing specific therapeutic areas and seeking partnerships to advance drug development programs. The focus on autoimmune diseases and the exploration of strategic options for oncology assets align with the industry's emphasis on targeted therapies and efficient resource allocation.

Comparison to Industry Standards

The company's approach to selectively modulate T cells with its Immuno-STAT platform is differentiated from conventional approaches that broadly activate the immune system.
The company's CUE-401 program is designed to foster the immunosuppressive features of TGFwith the synergistic properties of Il-2, which is a novel approach compared to IL-2 muteins and TNFR2 agonists.
The company's CUE-500 series is designed to selectively redirect prevalent and naturally occurring anti-viral killer T cells to mediate depletion of pathogenic cell types, which is a superior differentiation of the mechanism of action as compared to other competing modalities for target cell depletion, including CAR-T cellular therapy and pan-T cell engagers.
The company's CUE-100 series median overall survival, or mOS, of 2L+ patients treated at monotherapy doses greater than 1mg/kg is 20.8 months, which compares favorably to the historical third-party mOS data of 8.4 months with KEYTRUDA and 7.5 months with OPDIVO in the 2L setting.
The company's CUE-101 Phase 1b clinical trial investigating CUE-101 in combination with standard of care pembrolizumab (Keytruda), continues to mature with a mOS of 21.8 months and a 12-month landmark survival of 87.5% as of February 17, 2025, which appears favorable compared with the historical pembrolizumab mOS of 12.3 months.
The company's CUE-101 and pembrolizumab combination treatment has an objective response rate, or ORR, of 46%, compared to a 19% ORR for pembrolizumab alone from historic data.

Stakeholder Impact

Shareholders face potential dilution from future equity offerings.
Employees may be affected by the company's restructuring and prioritization of programs.
Patients with cancer and autoimmune diseases could benefit from the development of new therapies.
Suppliers and collaborators may be impacted by the company's strategic decisions and partnerships.
Creditors face risks associated with the company's financial condition and ability to repay debt.

Next Steps

Explore strategic options for the CUE-100 series in oncology.
Further position the CUE-401 program as a potentially disruptive, high-value opportunity.
Establish a third-party partnership to advance the preclinical CUE-501 program.
File an IND for CUE-401 in the third quarter of 2026.

Key Dates

Date	Description
January 14, 2015	Effective Date of the original Einstein License agreement.
March 23, 2016	Effective date of the 2016 Omnibus Incentive Plan.
July 31, 2017	Date of the amended and restated Einstein License agreement.
December 27, 2017	Completion of the initial public offering of common stock.
November 6, 2018	Date of the LG Chem Collaboration Agreement.
October 30, 2018	Date of a further amendment to the Einstein License agreement.
December 18, 2019	Date of the Global License and Collaboration Agreement with LG Chem.
March 2020	The United States Congress enacted the PPACA.
November 5, 2020	Date of amendment to the Global License and Collaboration Agreement with LG Chem.
February 15, 2022	Date of the Loan Agreement with Silicon Valley Bank.
March 28, 2022	Date of the License Agreement for the Boston headquarters.
April 15, 2022	Term Commencement Date of the License Agreement for the Boston headquarters.
May 3, 2022	Date of the First Amendment to the License Agreement for the Boston headquarters.
May 31, 2022	Date of the operating lease for additional laboratory space at 40 Guest Street.
December 1, 2022	Commencement of the operating lease for additional laboratory space at 40 Guest Street.
November 14, 2022	Date of the securities purchase agreements for the private placement.
November 16, 2022	Closing date of the private placement.
February 22, 2023	Date of the Ono Collaboration and Option Agreement.
April 2023	Date of the amendment to the Loan Agreement with Silicon Valley Bank.
March 10, 2023	Silicon Valley Bank closed and FDIC appointed receiver.
March 27, 2023	First Citizens Bank assumed SVB's deposits and certain assets.
September 26, 2024	Date of the Underwriting Agreement with Oppenheimer & Co. Inc.
October 2, 2024	Date of the Second Amendment to the Loan Agreement with Silicon Valley Bank.
November 20, 2024	Date of the Second Amendment to the Rider to License Agreement Vivarium.
December 31, 2024	Date of the end of the fiscal year.
January 21, 2025	President Trump revoked numerous executive orders issued by President Biden.
March 5, 2025	Effective date of the termination of the Ono Collaboration and Option Agreement.
March 11, 2025	Date of the Ninth Amendment to the LG Chem Collaboration Agreement.

Keywords

autoimmune, oncology, CUE-401, CUE-501, CUE-101, CUE-102, Immuno-STAT, clinical-stage, biopharmaceutical, T cells, immunotherapy, FDA, partnerships, financing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.